Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Strokes are affecting approximately 1.8 million people annually
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Subscribe To Our Newsletter & Stay Updated
